{
    "clinical_study": {
        "@rank": "139693", 
        "arm_group": {
            "arm_group_label": "OSAS Palatal Implant", 
            "arm_group_type": "Other", 
            "description": "The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate ."
        }, 
        "brief_summary": {
            "textblock": "The new OSAS Implant is intended for use in the palate (hard and soft palate/ see picture\n      above) in order to stiffen and stabilize the soft palate, which may reduce the severity of\n      airway obstructions and of snoring in patients suffering from OSA (Obstructive Sleep Apnea).\n      Indications for use of the System include: symptomatic, habitual, social snoring due to\n      palatal flutter or upper airway obstruction primarily caused by the retropalatal\n      obstruction. The System is labeled for use by physicians only.\n\n      The primary endpoint is the Apnea-Hypopnea-Index (AHI) in the 90 days follow-up.\n\n      Study hypothesis: Reduction of initial AHI \u226520%"
        }, 
        "brief_title": "Prospective Evaluation of a New Palatal Implant for Treatment of Snoring and Obstructive Sleep Apnea (OSAS)", 
        "condition": [
            "Reduction of Initial AHI by \u226520%", 
            "Reduction of Initial Snoaring Index by \u226530%."
        ], 
        "condition_browse": {
            "mesh_term": [
                "Sleep Apnea Syndromes", 
                "Sleep Apnea, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Study patients must meet all of the following inclusion criteria:\n\n          -  Socially disturbing snoring with/without obstructive sleep apnea syndrome\n\n          -  Predominantly retropalatal obstructions established by ApneaGraph       \u226560%, sleep\n             nasendoscopy or successful application of the Velumount palatal device\n\n          -  Findings for predominantly retropalatal obstructions in ENT-examination:\n\n          -  No tonsils or tonsils grade I - II\n\n          -  Normal finding of larynx and tongue base\n\n          -  No lingual tonsil hypertrophy\n\n          -  ASA (American Society of Anaesthesiology, 1963) criteria I or II\n\n          -  Body mass index (BMI) < 33 kg/m2\n\n          -  Age > 18 yrs\n\n          -  Fix bed partner\n\n          -  Ability to read and understand the patient's information\n\n        Exclusion Criteria:\n\n          -  Previous Pillar implants\n\n          -  Previous airway surgery other than nasal, adenoid, tonsil or UPPP\n\n          -  Presence of other sleep disorders\n\n          -  Psychiatric disorders\n\n          -  Neurological disorders (e.g. Cerebrovascular injury)\n\n          -  Dysmorphia of the cranial skeleton\n\n          -  Pregnancy or breastfeeding\n\n          -  Known hypersensitivity to nitinol\n\n          -  Participation in another clinical study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094482", 
            "org_study_id": "P08138.1"
        }, 
        "intervention": {
            "arm_group_label": "OSAS Palatal Implant", 
            "description": "The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate", 
            "intervention_name": "The IMD is a resilient palatal implant which is introduced through a stab incision into the palate.", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Basel", 
                    "country": "Switzerland", 
                    "state": "Baselland", 
                    "zip": "4410"
                }, 
                "name": "Kantonsspital Liestal"
            }, 
            "investigator": {
                "last_name": "Kurt Tschopp, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "official_title": "Prospective Evaluation of a New Palatal Implant for Treatment of Snoring and Obstructive Sleep Apnea (OSAS)", 
        "overall_contact": {
            "email": "kurt.tschopp@ksli.ch", 
            "last_name": "Kurt Tschopp, MD", 
            "phone": "+41 61 9252831"
        }, 
        "overall_contact_backup": {
            "email": "christoph.knaus@ksli.ch", 
            "last_name": "Christoph Knaus, MD", 
            "phone": "+4161 925 28 38"
        }, 
        "overall_official": {
            "affiliation": "Kantonsspital Liestal", 
            "last_name": "Kurt Tschopp, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the Apnea-Hypopnea-Index (AHI) at the 90 days follow-up.\nStudy hypothesis: Reduction of initial AHI \u226520%. AHI is measured using cardio-respiratory polygraphy. Two measurements are performed before treatment and at 90 days follow-up in order to reduce effects from night-to-night variability.", 
            "measure": "Reduction of initial AHI  by \u226520%", 
            "safety_issue": "No", 
            "time_frame": "90days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094482"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Endpoint snoring is measured on a continuous Visual Analog Scale (VAS) by the bed partner.\nStudy hypothesis: Reduction of initial snoring index \u226530%", 
            "measure": "Reduction of initial snoring index \u226530%", 
            "safety_issue": "No", 
            "time_frame": "90days"
        }, 
        "source": "Medartis AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medartis AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}